1. Giffin, Michael J, Cooke, Keegan, Lobenhofer, Edward K, Bailis, Julie M, Hughes, Paul E. 2020. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. In Clinical cancer research : an official journal of the American Association for Cancer Research, 27, 1526-1537. doi:10.1158/1078-0432.CCR-20-2845. https://pubmed.ncbi.nlm.nih.gov/33203642/
2. Yang, Ludi, Wang, Gaoming, Shi, Hanhan, Cui, Ran, Ge, Shengfang. 2022. Methylation-driven gene DLL3 is a potential prognostic biomarker in ocular melanoma correlating with metastasis. In Frontiers in oncology, 12, 964902. doi:10.3389/fonc.2022.964902. https://pubmed.ncbi.nlm.nih.gov/36338696/
3. Hipp, Susanne, Voynov, Vladimir, Drobits-Handl, Barbara, Scheer, Justin M, Adam, Paul J. 2020. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer. In Clinical cancer research : an official journal of the American Association for Cancer Research, 26, 5258-5268. doi:10.1158/1078-0432.CCR-20-0926. https://pubmed.ncbi.nlm.nih.gov/32554516/
4. Morgensztern, Daniel, Besse, Benjamin, Greillier, Laurent, Govindan, Ramaswamy, Carbone, David P. 2019. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. In Clinical cancer research : an official journal of the American Association for Cancer Research, 25, 6958-6966. doi:10.1158/1078-0432.CCR-19-1133. https://pubmed.ncbi.nlm.nih.gov/31506387/
5. Maimaiti, Aierpati, Wang, Xixian, Hao, Yujun, Feng, Zhaohai, Kasimu, Maimaitijiang. 2021. Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma. In Journal of molecular neuroscience : MN, 71, 1622-1635. doi:10.1007/s12031-021-01817-7. https://pubmed.ncbi.nlm.nih.gov/33713320/
6. Puca, Loredana, Gavyert, Katie, Sailer, Verena, Saunders, Laura, Beltran, Himisha. . Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. In Science translational medicine, 11, . doi:10.1126/scitranslmed.aav0891. https://pubmed.ncbi.nlm.nih.gov/30894499/
7. Ajkunic, Azra, Sayar, Erolcan, Roudier, Martine P, Nelson, Peter S, Haffner, Michael C. 2024. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. In NPJ precision oncology, 8, 104. doi:10.1038/s41698-024-00599-6. https://pubmed.ncbi.nlm.nih.gov/38760413/
8. Xiang, Jinyu, Gong, Wenjing, Liu, Jiannan, Lv, Yaodong, Sun, Ping. 2023. Identification of DLL3-related genes affecting the prognosis of patients with colon adenocarcinoma. In Frontiers in genetics, 14, 1098190. doi:10.3389/fgene.2023.1098190. https://pubmed.ncbi.nlm.nih.gov/37274780/
智鼠故事 
